Melvin Spigelman - Concepedia

Author

Melvin Spigelman

Also Known As

M K Spigelman, M Spigelman, M. K. Spigelman, M. Spigelman, M.K. SPIGELMAN, Melvin K Spigelman, Melvin K. SPIGELMAN, Melvin K. Spigelman, Melvin K. Spigelman M.D., Melvin Spigelman

Publications

6.3K

Citations

H-Index

Concepts

All Affiliations

TB Alliance Task Applied Science University College London University of Cape Town Stellenbosch University

About

Melvin Spigelman is an author at TB Alliance specializing in medicine, pharmacology, and drug resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.3K
2	Health Sciences	4	4	378
3	Neurology	3	3	68
4	Microbiology	2	2	562
5	Social Sciences	1	1	15

Melvin Spigelman

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis Francesca Conradie, Andreas H. Diacon, Nosipho Ngubane, New England Journal of Medicine	2020	962
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Francesca Conradie, Tatevik R. Bagdasaryan, Pauline Howell, New England Journal of Medicine	2022	507
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial Andreas H. Diacon, Rodney Dawson, Florian von Groote-Bidlingmaier, The Lancet AntibioticsMedicineRandomised Trial14-Day Bactericidal ActivityAntibacterial Agent	2012	428
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis, New England Journal of Medicine	2022	318
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt, The Lancet Pulmonary TuberculosisPhase 2BTuberculosis PreventionPharmacologyTuberculosis	2015	248
Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients Andreas H. Diacon, Rodney Dawson, M. Hanekom, Antimicrobial Agents and Chemotherapy Tuberculosis PreventionBactericidal ActivityPharmacotherapyAntimicrobial ChemotherapyDrug Resistance	2010	175
Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects Ann M. Ginsberg, Martino Laurenzi, D.J. Rouse, Antimicrobial Agents and Chemotherapy Drug SafetyPulmonary TuberculosisSteady StateHealthy SubjectsAntibiotics	2009	147
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial Conor Tweed, Rodney Dawson, Divan A. Burger, The Lancet Respiratory Medicine	2019	143
Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824 Andreas H. Diacon, Rodney Dawson, Jeannine du Bois, Antimicrobial Agents and Chemotherapy Tuberculosis PreventionBacteriophagePharmacotherapyAntimicrobial ChemotherapyDrug Resistance	2012	134
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis, The Lancet Respiratory Medicine	2023	79

Page 1